Supernus Pharma (SUPN) Misses Q4 EPS by 54c ; Offers Guidance

Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.02, $0.54 worse than the analyst estimate of $0.56. Revenue for the quarter came in at $156 million versus the consensus estimate of $155.83 million.

GUIDANCE:

Supernus Pharma sees FY2024 revenue of $580-620 million, versus the consensus of $622.5 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained
• Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold